Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder
Links shared publicly online about this topic.
- 0total visits
Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder
View full resource at news-medical.net
Tags: Asthma, Spasmodic Torticollis Medication, Overactive Bladder, Botox, Allergan, News, Bladder Dysfunction, Wrinkle Relaxer
Most Recently Shared on March 29, 2012 at 7:13 am By:
Asthma News: Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder: Allergan,... http://t.co/k1gzQMTW
Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder
news-medical.net — “Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.” View full resource at news-medical.net
Most Recently Shared on March 29, 2012 at 8:01 am By:
Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder: Allergan, Inc. today a... http://t.co/cDU8XmKG
Allergan Announces Positive Top-Line Results from Phase III BOTOX Overactive Bladder Program - Drugs.com MedNews
drugs.com — “Phase III Studies Show Statistically Significant Decrease Mar 28, 2012 - Allergan, Inc. (NYSE AGN) today announced that two Phase III clinical trials of BOTOX (” View full resource at drugs.com
Most Recently Shared on March 28, 2012 at 3:16 pm By:
Drugs and Devices OW OW Health
Allergan Announces Positive Top-Line Results from Phase III BOTOX Overactive Bladder Program: -- Phase III... http://t.co/WgOjILAz #drug
Allergan Announces Positive Top-Line Results from Phase III BOTOX® Overactive Bladder Program - Yahoo! News
news.yahoo.com — “From Yahoo! News: Allergan, Inc. (NYSE: AGN) today announced that two Phase III clinical trials of BOTOX® (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints. Results from both Phase III clinical trials demonstrate that BOTOX® significantly reduced urinary incontinence (bladder leakage) episodes compared to placebo for the treatment of overactive bladder patients with urinary incontinence who were not adeq” View full resource at news.yahoo.com
Most Recently Shared on March 28, 2012 at 1:38 pm By:
Allergan Announces Positive Top-Line Results from Phase III BOTOX® Overactive Bladder Program: Allergan, Inc. (N... http://t.co/L7vTRp48
Advertisement
